Almirall is a global biopharmaceutical company specializing in dermatology. The company develops and commercializes solutions for the treatment of a variety of dermatological diseases such as acne, atopic dermatitis, actinic keratosis, vitiligo, onychomycosis, skin cancer, and psoriasis, among others. Some of the company’s key products are Wynora cream (for mild-to-moderate plaque psoriasis), Skilarence (for moderate-to-severe plaque psoriasis), and Actikerall (for hyperkeratotic actinic keratosis). The company also produces medicines for neurological, gastric, and cardiac diseases. The company sells a total of 143 products, of which 51 are for skin diseases.
The report provides information and insights into Almirall's tech activities, including:
- Insights of its digital transformation strategies and innovation programs.
- Overview of technology initiatives covering partnerships and product launches.
- Insights on each technology initiative including technology theme, objective, and benefits.
- Details of estimated ICT budgets and major ICT contracts.
Scope
- The report provides insights into the company’s tech activities, including its digital transformation strategies, its innovation programs, and its technology initiatives.
Reasons to Buy
- Gain insights into Almirall's tech operations.
- Gain insights into its tech strategies and innovation initiatives.
- Gain insights into its technology themes under focus.
- Gain insights into various product launches and partnerships.
Table of Contents
- Overview
- Digital Transformation Strategy
- Accelerators, Incubators, and Other Innovation Programs
- Technology Focus
- Technology Initiatives
- Partnerships Network Map
- ICT Budget and Contracts
- Key Executives
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Microsoft
- Barcelona Supercomputing Center-Centro Nacional de Supercomputación (BSC-CNS)
- Nostrum Biodiscovery
- NTT Data
- ZeClinics
- Absci Corporation
- Aktana
- Iktos
- Clariba
